Context Therapeutics buys out future milestones and royalties for CT-202 from BioAtla for $6.5M total

Context Therapeutics Inc.

Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.
License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.
BioAtla no longer entitled to future milestones or royalties for CT-202.
Phase 1 trial initiation for CT-202 expected in Q3 2026.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.